The use of immune checkpoint inhibitors (ICI) such as programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) has become one of the most promising approaches in the field of cancer therapy. Here, PDCD1 is linked to cancer.